AzTrials
AzTrials

Cystic FibrosisNCT03069625

Sit-to-stand Test in Cystic Fibrosis Children and Adolescents

A study testing Sit-to-stand test and 6-Minute Walk Test in people with Cystic Fibrosis, run by Groupe Hospitalier du Havre at 3 sites in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Cystic fibrosis (CF) is a chronic hereditary respiratory disease. Exercise testing is part of CF patients regular assessment. Cardio-Pulmonary Exercise Testing (CPET) is currently considered as the gold standard to assess physical capacities. However, simple field tests are emerging. Read more about this study

Who is it for?
Ages 6 to 18 years
Conditions the study is for
Cystic Fibrosis
What is being tested?
Sit-to-stand test and 6-Minute Walk Test
Could I receive a placebo?
No, everyone receives an active treatment
How many people
36 participants
Where
3 sitesFrance
Study dates
31 Aug 2017to 24 Jul 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 18 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • Cystic Fibrosis
  • Exacerbation-free last month before inclusion

Who cannot join

  • Cardiovascular, neurological or musculoskeletal contra-indications to exercise testing
  • Other respiratory disease (kyphoscoliosis, asthma ...)
  • Exacerbation
  • Unability to carry out field tests

Trial locations and contacts

3 sites in 1 country.

France3 sites
  • Hôpital Côte de Nacre

    Caen

  • Le Havre Hospital

    Le Havre, 76290

  • CHU de Rouen

    Rouen, 76000

Other trials in France

About this study

Official title: Sit-to-stand Test Use in Children and Adolescents With Cystic Fibrosis : Correlations With 6-Minute Walking Test, Quadriceps and Respiratory Muscle Strength and Health Related Quality of Life

Cystic fibrosis (CF) is a chronic hereditary respiratory disease. Exercise testing is part of CF patients regular assessment.

Cardio-Pulmonary Exercise Testing (CPET) is currently considered as the gold standard to assess physical capacities. However, simple field tests are emerging. These tests are easier to perform especially in a population of CF children and adolescents.

Read more

The 1minute Sit-To-Stand test have recently been evaluated in CF adults. This test correlates with maximal oxygen consumption during CPET.

The investigators hypothesized that this test also correlates with 6-Minute Walking distance (during a 6-min Walk Test), quadriceps strength, respiratory muscles strength and health-related quality of life.

Conditions
Cystic Fibrosis
Being tested
Sit-to-stand test, 6-Minute Walk Test
Keywords
Cystic Fibrosis, Exercise Testing, Muscular strength, Pediatrics, Quality of life
Medical subject headings
Cystic Fibrosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Sit-to-stand testBehavioural

    CF young patients will perform 2 STS tests. Number of repetitions, cardio-respiratory response and physiological adaptations during the second test will be monitored.

  • 6-Minute Walk TestBehavioural

    CF young patients will perform 2 6MWT tests. Number of repetitions, cardio-respiratory response and physiological adaptations during the second test will be monitored.

Study groups in NCT03069625
Study groupRoleWhat they receive
Sit-to-stand testExperimentalChildren and adolescents will perform 2 STS tests. First one is used to eliminate learning effect. Number of repetitions will be noted at the end of the second test.
Receives: Behavioral: Sit-to-stand test
6-Minute Walk TestActive comparatorChildren and adolescents will perform 2 6MWT tests. First one is used to eliminate learning effect. Number of repetitions will be noted at the end of the second test.
Receives: Behavioral: 6-Minute Walk Test

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Correlation between number of repetitions (STS Test) and 6-Minute Walking Distance

    Comparison between the results of these two submaximal exercise tests

    Measured: This outcome will be measured after both tests realization up to 15 minutes.

Secondary outcomes (11)
  1. Correlation between number of repetitions (STS test) and Maximal Inspiratory Pressure (MIP)

    MIP will be assessed using a microRPM Puma manometer.

    Measured: MIP will be measured after inclusion in the hour before field tests realization.

  2. Correlation between number of repetitions (STS test) and Maximal Expiratory Pressure (MEP)

    MEP will be assessed using a MicroRPM Puma manometer.

    Measured: MEP will be measured after inclusion in the hour before field tests realization.

  3. Correlation between number of repetitions (STS Test) and health-related quality of life

    HRQoL will be measured by the Cystic Fibrosis Questionnaire

    Measured: HRQoL testing will be carried out after inclusion in the hour before field tests realization.

  4. Correlation between number of repetitions (STS Test) and quadriceps strength.

    Quadriceps strength will be assessed by handheld dynamometry using a MicroFet II dynamometer.

    Measured: Quadriceps strength will be assessed after inclusion in the hour before field tests realization.

  5. Correlation between number of repetitions (STS Test) and forced vital capacity (FVC)

    FVC will be assessed with non invasive spirometry.

    Measured: Spirometric test will be carried out before field tests realization.

  6. Correlation between number of repetitions (STS Test) and forced expiratory volume in 1 second (FEV1)

    FEV1 will be assessed with non invasive spirometry.

    Measured: Spirometric test will be carried out in the last 3 months before field tests realization.

  7. Correlation between number of repetitions (STS Test) and number of exacerbations / year.

    Measured: Number of exacerbations / year will assess the number of exacerbations in the last year before inclusion and will be assessed during the initial survey in the hour before field test realization.

  8. Differences in dyspnea and muscular fatigue.

    These outcomes will be assessed using Modified Borg Scale (0-10 points)

    Measured: These outcomes will be assessed during both field tests. These tests will be separate by a 30 minutes rest period. Date will be collected at the end of each test up to 15 minutes.

  9. Differences in Heart Rate.

    These outcomes will be assessed using pulse oximetry.

    Measured: These outcomes will be assessed during both field tests. These tests will be separate by a 30 minutes rest period. Date will be collected at the end of each test up to 15 minutes.

  10. Differences in Respiratory Rate.

    These outcomes will be assessed using pulse oximetry.

    Measured: These outcomes will be assessed during both field tests. These tests will be separate by a 30 minutes rest period. Date will be collected at the end of each test up to 15 minutes

  11. Differences in Oxygen Saturation.

    These outcomes will be assessed using pulse oximetry.

    Measured: These outcomes will be assessed during both field tests. These tests will be separate by a 30 minutes rest period. Date will be collected at the end of each test up to 15 minutes.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Mar 2017
  2. Study start31 Aug 2017
  3. Primary completion24 Jul 2019
  4. Study completion24 Jul 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Screening
Allocation
Randomised
Intervention model
Crossover
Masking
None (open label)
Enrolment
36 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03069625
Sponsor's protocol ID
2016-A01377-44
Status last verified
May 2019
First submitted
16 Feb 2017
Last updated
3 Sep 2019
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Radtke T, Puhan MA, Hebestreit H, Kriemler S. The 1-min sit-to-stand test--A simple functional capacity test in cystic fibrosis? J Cyst Fibros. 2016 Mar;15(2):223-6. doi: 10.1016/j.jcf.2015.08.006. Epub 2015 Sep 9.

    PubMed 26363563
  • Ozalevli S, Ozden A, Itil O, Akkoclu A. Comparison of the Sit-to-Stand Test with 6 min walk test in patients with chronic obstructive pulmonary disease. Respir Med. 2007 Feb;101(2):286-93. doi: 10.1016/j.rmed.2006.05.007. Epub 2006 Jun 27.

    PubMed 16806873
  • Hussey J, Gormley J, Leen G, Greally P. Peripheral muscle strength in young males with cystic fibrosis. J Cyst Fibros. 2002 Sep;1(3):116-21. doi: 10.1016/s1569-1993(02)00074-7.

    PubMed 15463817
  • Combret Y, Boujibar F, Gennari C, Medrinal C, Sicinski S, Bonnevie T, Gravier FE, Laurans M, Marguet C, Le Roux P, Lamia B, Prieur G, Reychler G. Measurement properties of the one-minute sit-to-stand test in children and adolescents with cystic fibrosis: A multicenter randomized cross-over trial. PLoS One. 2021 Feb 12;16(2):e0246781. doi: 10.1371/journal.pone.0246781. eCollection 2021.

    PubMed 33577586

Questions about this trial

What is this clinical trial studying?

A study testing Sit-to-stand test and 6-Minute Walk Test in people with Cystic Fibrosis, run by Groupe Hospitalier du Havre at 3 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Sep 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Correlation between number of repetitions (STS Test) and 6-Minute Walking Distance (time frame: This outcome will be measured after both tests realization up to 15 minutes.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03069625, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Sep 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in